Skip to main content

Table 5 Predictors of TTP

From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

 

Univariable

Multivariable

HR

95% CI

p-value

aHR

95% CI

p-value

Age > 60 yr

0.73

0.53–1.00

0.049

   

Male

0.75

0.47–1.18

0.213

   

PIVKA II > 250 mAU/mL

1.29

0.93–1.80

0.133

   

AFP > 200 ng/mL

1.96

1.42–2.72

 < 0.001

1.98

1.42–2.75

 < 0.001

Total bilirubin

1.02

0.92–1.14

0.663

   

Albumin

1.18

0.888–1.59

0.264

   

ALT

1.00

1.00–1.00

0.668

   

AST

1.00

1.00–1.00

0.236

   

PT

1.48

0.88–2.47

0.139

   

Presence of ascites

0.97

0.66–1.42

0.867

   

ECOG 1 (vs 0)

1.53

1.07–2.17

0.019

   

Child B,C (vs A)

0.89

0.60–1.32

0.558

   

BCLC stage C,D (vs B)

1.43

0.83–2.48

0.200

   

Tumor size

1.00

1.00–1.00

0.828

   

Extrahepatic metastasis

1.17

0.83–1.65

0.373

   

Portal vein thrombosis

1.05

0.76–1.44

0.787

   

Biliary invasion

1.20

0.63–2.28

0.576

   

Lenvatinib (vs sorafenib)

0.55

0.37–0.84

0.005

0.55

0.36–0.84

0.005

Previous anti-HCC treatment

0.99

0.63–1.57

0.966

   
  1. Multivariable analysis was performed using variables with p value under 0.05 at univariable analysis
  2. HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; PIVKA, protein induced by vitamin K absence or antagonists-II; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us